IDEAS home Printed from https://ideas.repec.org/f/pjo397.html
   My authors  Follow this author

Geoffrey Joyce

Personal Details

First Name:Geoffrey
Middle Name:
Last Name:Joyce
Suffix:
RePEc Short-ID:pjo397

Affiliation

Leonard D. Schaeffer Center for Health Policy and Economics
University of Southern California

Los Angeles, California (United States)
http://healthpolicy.usc.edu/
RePEc:edi:chuscus (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Chapters

Working papers

  1. Mariana Carrera & Dana Goldman & Geoffrey Joyce, 2013. "Heterogeneity in Cost-Sharing and Cost-Sensitivity, and the Role of the Prescribing Physician," NBER Working Papers 19186, National Bureau of Economic Research, Inc.

Articles

  1. Mariana Carrera & Dana P. Goldman & Geoffrey Joyce & Neeraj Sood, 2018. "Do Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 113-152, February.
  2. Joyce, Geoffrey F. & Zissimopoulos, Julie & Goldman, Dana P., 2013. "Digesting the doughnut hole," Journal of Health Economics, Elsevier, vol. 32(6), pages 1345-1355.
  3. Goldman Dana P & Joyce Geoffrey & Karaca-Mandic Pinar & Sood Neeraj, 2006. "Adverse Selection in Retiree Prescription Drug Plans," Forum for Health Economics & Policy, De Gruyter, vol. 9(1), pages 1-25, December.
  4. Goldman Dana P & Cutler David M & Shang Baoping & Joyce Geoffrey F, 2006. "The Value of Elderly Disease Prevention," Forum for Health Economics & Policy, De Gruyter, vol. 9(2), pages 1-29, January.
  5. Bhattacharya Jayanta & Cutler David M. & Goldman Dana P. & Hurd Michael D. & Joyce Geoffrey F. & Lakdawalla Darius N. & Panis Constantijn W. A. & Shang Baoping, 2004. "Disability Forecasts and Future Medicare Costs," Forum for Health Economics & Policy, De Gruyter, vol. 7(1), pages 1-22, January.
  6. Goldman Dana P & Joyce Geoffrey F & Malkin Jesse Dylan, 2002. "The Costs of A Medicare Prescription Drug Benefit," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 2(1), pages 1-18, April.
  7. Zingmond, D.S. & Wenger, N.S. & Crystal, S. & Joyce, G.F. & Liu, H. & Sambamoorthi, U. & Lillard, L.A. & Leibowitz, A.A. & Shapiro, M.F. & Bozzette, S.A., 2001. "Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans," American Journal of Public Health, American Public Health Association, vol. 91(7), pages 1117-1120.

Chapters

  1. Dana P. Goldman & Geoffrey Joyce & Pinar Karaca-Mandic & Neeraj Sood, 2006. "Adverse Selection in Retiree Prescription Drug Plans," NBER Chapters, in: Frontiers in Health Policy Research, Volume 9, National Bureau of Economic Research, Inc.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Mariana Carrera & Dana Goldman & Geoffrey Joyce, 2013. "Heterogeneity in Cost-Sharing and Cost-Sensitivity, and the Role of the Prescribing Physician," NBER Working Papers 19186, National Bureau of Economic Research, Inc.

    Cited by:

    1. Tianyan Hu & Sandra L. Decker & Shin-Yi Chou, 2014. "The Impact of Health Insurance Expansion on Physician Treatment Choice: Medicare Part D and Physician Prescribing," NBER Working Papers 20708, National Bureau of Economic Research, Inc.
    2. Vincenzo Atella & Federico Belotti & Domenico Depalo, 2017. "Drug therapy adherence and health outcomes in the presence of physician and patient unobserved heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 26(S2), pages 106-126, September.
    3. Niels Skipper & Rune Vejlin, 2013. "Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data," Economics Working Papers 2013-05, Department of Economics and Business Economics, Aarhus University.

Articles

  1. Mariana Carrera & Dana P. Goldman & Geoffrey Joyce & Neeraj Sood, 2018. "Do Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 113-152, February.

    Cited by:

    1. Villas-Boas, Sofia B & Carrera, Mariana, 2016. "Generic aversion and observational learning in the over-the-counter drug market," Department of Agricultural & Resource Economics, UC Berkeley, Working Paper Series qt0q03b5f2, Department of Agricultural & Resource Economics, UC Berkeley.
    2. Christian Posso & Jorge Tamayo & Arlen Guarin & Estefania Saravia, 2024. "Luck of the Draw: The Causal Effect of Physicians on Birth Outcomes," Borradores de Economia 1269, Banco de la Republica de Colombia.
    3. Newham, Melissa & Valente, Marica, 2024. "The cost of influence: How gifts to physicians shape prescriptions and drug costs," Journal of Health Economics, Elsevier, vol. 95(C).
    4. Laura V Minard & Amber Corkum & Ingrid Sketris & Judith Fisher & Ying Zhang & Ahmed Saleh, 2016. "Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-15, July.
    5. Rabideau, Brendan & Eisenberg, Matthew D. & Reid, Rachel & Sood, Neeraj, 2021. "Effects of employer-offered high-deductible plans on low-value spending in the privately insured population," Journal of Health Economics, Elsevier, vol. 76(C).
    6. Magno, Cielo & Guzman, Ricardo Rafael S., 2019. "Drug price sensitivity among physicians in a developing healthcare system: Evidence from the Philippine market for statins and beta blockers," Economic Analysis and Policy, Elsevier, vol. 62(C), pages 268-279.
    7. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
    8. Sebastian Linde & Brandon Norton & Ralph Siebert, 2019. "The Effect of Bargaining Power Determinants on Pharmaceutical Prices," CESifo Working Paper Series 7988, CESifo.
    9. Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2021. "Paying for pharmaceuticals: uniform pricing versus two-part tariffs," NIPE Working Papers 01/2021, NIPE - Universidade do Minho.
    10. Ghosh, Ausmita & Simon, Kosali & Sommers, Benjamin D., 2019. "The Effect of Health Insurance on Prescription Drug Use Among Low-Income Adults:Evidence from Recent Medicaid Expansions," Journal of Health Economics, Elsevier, vol. 63(C), pages 64-80.
    11. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Other publications TiSEM be3f3c38-5e39-4a67-af57-8, Tilburg University, School of Economics and Management.
    12. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-034, Tilburg University, Tilburg Law and Economic Center.
    13. Wu, Bingxiao, 2019. "Physician agency in China: Evidence from a drug-percentage incentive scheme," Journal of Development Economics, Elsevier, vol. 140(C), pages 72-89.
    14. Lee, Chung-Ying, 2020. "Pricing strategy and moral hazard: Copay coupons in pharmaceuticals," International Journal of Industrial Organization, Elsevier, vol. 70(C).
    15. Christopher Bates & Susan J. Méndez, 2024. "Therapeutic Substitution in Response to Patent Expiry? Statins in Australia," Economic Papers, The Economic Society of Australia, vol. 43(2), pages 112-123, June.
    16. Meng-Chi Tang & Yi-Nong Wu, 2020. "Medical providers as double agents in a universal health care system: evidence from generic pharmaceutical adoption in Taiwan," Empirical Economics, Springer, vol. 59(1), pages 169-203, July.
    17. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Other publications TiSEM 6ee607fc-8602-4270-a076-3, Tilburg University, School of Economics and Management.
    18. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).

  2. Joyce, Geoffrey F. & Zissimopoulos, Julie & Goldman, Dana P., 2013. "Digesting the doughnut hole," Journal of Health Economics, Elsevier, vol. 32(6), pages 1345-1355.

    Cited by:

    1. Liran Einav & Amy Finkelstein & Raymond Kluender & Paul Schrimpf, 2015. "Beyond Statistics: The Economic Content of Risk Scores," NBER Working Papers 21304, National Bureau of Economic Research, Inc.
    2. Judith Liu & Yuting Zhang & Cameron M. Kaplan, 2023. "Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs," Health Economics, John Wiley & Sons, Ltd., vol. 32(3), pages 639-653, March.
    3. Naomi C. Sacks & James F. Burgess & Howard J. Cabral & Steven D. Pizer, 2017. "Myopic and Forward Looking Behavior in Branded Oral Anti‐Diabetic Medication Consumption: An Example from Medicare Part D," Health Economics, John Wiley & Sons, Ltd., vol. 26(6), pages 753-764, June.

  3. Goldman Dana P & Joyce Geoffrey & Karaca-Mandic Pinar & Sood Neeraj, 2006. "Adverse Selection in Retiree Prescription Drug Plans," Forum for Health Economics & Policy, De Gruyter, vol. 9(1), pages 1-25, December.

    Cited by:

    1. Carey, Colleen, 2021. "Sharing the burden of subsidization: Evidence on pass-through from a subsidy revision in Medicare Part D," Journal of Public Economics, Elsevier, vol. 198(C).
    2. Colleen Carey, 2017. "Technological Change and Risk Adjustment: Benefit Design Incentives in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, vol. 9(1), pages 38-73, February.
    3. Murat K. Munkin & Pravin K. Trivedi, 2010. "Disentangling incentives effects of insurance coverage from adverse selection in the case of drug expenditure: a finite mixture approach," Health Economics, John Wiley & Sons, Ltd., vol. 19(9), pages 1093-1108, September.
    4. Munkin M & Trivedi P. K, 2009. "Incentives and Selection Effects of Drug Coverage on Total Drug Expenditure: a Finite Mixture Approach," Health, Econometrics and Data Group (HEDG) Working Papers 09/22, HEDG, c/o Department of Economics, University of York.

  4. Goldman Dana P & Cutler David M & Shang Baoping & Joyce Geoffrey F, 2006. "The Value of Elderly Disease Prevention," Forum for Health Economics & Policy, De Gruyter, vol. 9(2), pages 1-29, January.

    Cited by:

    1. Vincenzo Atella & Federico Belotti & Daejung Kim & Dana Goldman & Tadeja Gracner & Andrea Piano Mortari & Bryan Tysinger, 2021. "The future of the elderly population health status: Filling a knowledge gap," Health Economics, John Wiley & Sons, Ltd., vol. 30(S1), pages 11-29, November.
    2. P.-C. Michaud & D. Goldman & D. Lakdawalla & A. Gailey & Y. Zheng, 2009. "International Differences in Longevity and Health and their Economic Consequences," Social and Economic Dimensions of an Aging Population Research Papers 254, McMaster University.
    3. Knai, Cecile & Suhrcke, Marc & Lobstein, Tim, 2007. "Obesity in Eastern Europe: An overview of its health and economic implications," Economics & Human Biology, Elsevier, vol. 5(3), pages 392-408, December.
    4. Jinjing Li & Cathal O'Donoghue, 2013. "A survey of dynamic microsimulation models: uses, model structure and methodology," International Journal of Microsimulation, International Microsimulation Association, vol. 6(2), pages 3-55.
    5. Suhrcke, Marc & Urban, Dieter M. & Moesgaard Iburg, Kim & Schwappach, David & Boluarte, Till & McKee, Martin, 2007. "The economic benefits of health and prevention in a high-income country: the example of Germany," Discussion Papers, Research Group Public Health SP I 2007-302, WZB Berlin Social Science Center.
    6. Julia Thornton Snider & Jeffrey Sullivan & Emma van Eijndhoven & Michael K Hansen & Nobel Bellosillo & Cheryl Neslusan & Ellen O’Brien & Ralph Riley & Seth Seabury & Bertram L Kasiske, 2019. "Lifetime benefits of early detection and treatment of diabetic kidney disease," PLOS ONE, Public Library of Science, vol. 14(5), pages 1-13, May.

  5. Bhattacharya Jayanta & Cutler David M. & Goldman Dana P. & Hurd Michael D. & Joyce Geoffrey F. & Lakdawalla Darius N. & Panis Constantijn W. A. & Shang Baoping, 2004. "Disability Forecasts and Future Medicare Costs," Forum for Health Economics & Policy, De Gruyter, vol. 7(1), pages 1-22, January.

    Cited by:

    1. Niehaus, Frank, 2006. "Alter und steigende Lebenserwartung - Eine Analyse der Auswirkungen auf die Gesundheitsausgaben," WIP-Analysen Dezember 2006, WIP – Wissenschaftliches Institut der PKV.
    2. Niehaus, Frank, 2008. "Prognose des Beitragssatzes in der gesetzlichen Krankenversicherung," WIP-Analysen September 2008, WIP – Wissenschaftliches Institut der PKV.
    3. P.-C. Michaud & D. Goldman & D. Lakdawalla & Y. Zheng & A. Gailey, 2009. "Understanding the Economic Consequences of Shifting Trends in Population Health," Social and Economic Dimensions of an Aging Population Research Papers 255, McMaster University.
    4. Igor Akushevich & Julia S. Kravchenko & Kenneth G. Manton, 2007. "Health‐Based Population Forecasting: Effects of Smoking on Mortality and Fertility," Risk Analysis, John Wiley & Sons, vol. 27(2), pages 467-482, April.
    5. Gregory G. Lubiani & Albert A. Okunade, 2013. "Production Cost Structure In Us Outpatient Physical Therapy Health Care," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 212-223, February.
    6. Niehaus, Frank & Weber, Christian, 2008. "Teilkapitaldeckung als Finanzierungsmodell am Beispiel der Pflegeversicherung," WIP-Analysen Juni 2008, WIP – Wissenschaftliches Institut der PKV.

  6. Goldman Dana P & Joyce Geoffrey F & Malkin Jesse Dylan, 2002. "The Costs of A Medicare Prescription Drug Benefit," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 2(1), pages 1-18, April.

    Cited by:

    1. Dahlia K. Remler & Joshua Graff Zivin & Sherry A. Glied, 2002. "Modeling Health Insurance Expansions: Effects of Alternate Approaches," NBER Working Papers 9130, National Bureau of Economic Research, Inc.
    2. Melissa Boyle, 2008. "Costs and Benefits of Elderly Prescription Drug Coverage: Evidence from Veterans’ Health Care," Working Papers 0803, College of the Holy Cross, Department of Economics.

Chapters

  1. Dana P. Goldman & Geoffrey Joyce & Pinar Karaca-Mandic & Neeraj Sood, 2006. "Adverse Selection in Retiree Prescription Drug Plans," NBER Chapters, in: Frontiers in Health Policy Research, Volume 9, National Bureau of Economic Research, Inc.
    See citations under working paper version above.Sorry, no citations of chapters recorded.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Geoffrey Joyce should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.